Novel chmosensitivity testing using molecular dynamics responding to anticancer drugs
利用对抗癌药物的分子动力学进行新型化学敏感性测试
基本信息
- 批准号:17591435
- 负责人:
- 金额:$ 2.24万
- 依托单位:
- 依托单位国家:日本
- 项目类别:Grant-in-Aid for Scientific Research (C)
- 财政年份:2005
- 资助国家:日本
- 起止时间:2005 至 2006
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Purpose : To evaluate whether changes in the expression of early-response genes (GADD153, p21, and c-Jun) can indicate chemotherapy response in gastric cancer.Experimental Design : Three human gastric cancer cell lines (TMK-1,MKN-45, and MKN-74) were exposed to 5-fluorouracil (5-FU) or cisplatin (CDDP) in vitro. Xenografts of TMK-1 in nude mice were also treated with 5-FU or CDDP in vivo. For each of these treatments, we tested for a correlation between early gene expression levels and inhibition ratios (IR) derived at a later time. Finally, S-1 and CDDP were administered to 12 patients with advanced gastric cancer for three weeks. Among patients in different response groups, expression levels of GADD153, p21, and c-Jun were compared using biopsy specimens that were obtained by endoscopy soon after initiation of chemotherapy.Results : There was a significant correlation between the expression levels of these genes at 24 hours (as measured by real-time PCR) and IRs at 72 hours in vitro … More (GADD153;r=0.89, P<0.001, p21;r=0.93, P<0.001, and c-Jun; r=0.80, P<0.001). Receiver-operating characteristic (ROC) curves revealed that the cut-off values (calculated to predict the effectiveness of chemotherapy) for GADD153, p21, and c-Jun were 1.3, 1.8, and 2.1, respectively. There was also a significant correlation between gene expression levels at 2 days and IRs at 21 days in vivo (GADD153;r = 0.77, P<0.001, p21;r = 0.85, P<0.001, and c-Jun ; r = 0.87, P<0.001). ROC curves defined the cut-off values as 1.8 for GADD153, 1.9 for p21, and 2.2 for c-Jun. In clinical Gene Expression and Response Prediction studies, levels of early-response gene expressions at 3-7 days in patients showing progressive disease (PD) were significant lower than those in patients with partial response (PR) (GADD153;P=0.002, P21;P = 0.003, and c-Jun ; P=0.033).Conclusions : These results suggest that changes in the expression of the three early response genes soon after drug administration could improve predictions of the final outcome of chemotherapy in gastric cancer. Less
目的:探讨胃癌早期反应基因(GADD153、p21、c-Jun)的表达变化是否能提示化疗反应。实验设计:将3株人胃癌细胞株TMK-1、MKN-45和MKN-74体外暴露于5-氟尿嘧啶(5-FU)或顺铂(CDDP)。裸鼠移植的TMK-1也在体内用5-FU或CDDP处理。对于每一种治疗方法,我们都测试了早期基因表达水平与后期获得的抑制比(IR)之间的相关性。最后对12例晚期胃癌患者给予S-1和CDDP治疗3周。在不同反应组的患者中,使用化疗开始后不久内窥镜获得的活检标本比较GADD153, p21和c-Jun的表达水平。结果:这些基因在体外培养24小时(实时荧光定量PCR)的表达量与体外培养72小时的IRs有显著的相关性…More (GADD153, r=0.89, P<0.001, p21;r=0.93, P<0.001, c-Jun, r=0.80, P<0.001)。受试者工作特征(ROC)曲线显示,GADD153、p21和c-Jun的截止值(计算用于预测化疗的有效性)分别为1.3、1.8和2.1。2天的基因表达水平与体内21天的IRs也存在显著相关性(GADD153, r = 0.77, P<0.001, p21, r = 0.85, P<0.001, c-Jun, r = 0.87, P<0.001)。ROC曲线定义GADD153的临界值为1.8,p21为1.9,c-Jun为2.2。在临床基因表达和反应预测研究中,进展性疾病(PD)患者3-7天的早期反应基因表达水平显著低于部分反应(PR)患者(GADD153, P=0.002, P21, P= 0.003, c-Jun, P=0.033)。结论:这些结果表明,在给药后不久,三种早期反应基因的表达变化可以提高对胃癌化疗最终结果的预测。少
项目成果
期刊论文数量(28)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Chemosensitivity and resistance testing : to be "standard" or to be individualized, that is the question.
化学敏感性和耐药性测试:是“标准”还是个体化,这是个问题。
- DOI:
- 发表时间:2006
- 期刊:
- 影响因子:0
- 作者:Kubota T;et al.
- 通讯作者:et al.
Endoscopic classifications as diagnostic factors of peptic ulcer and early gastric cancer - a possible reason why Helicobacter pylori infection causes gastric ulcers along lesser curvature.
内镜分类作为消化性溃疡和早期胃癌的诊断因素——幽门螺杆菌感染导致胃小弯溃疡的可能原因。
- DOI:
- 发表时间:2006
- 期刊:
- 影响因子:0
- 作者:Yoshida;M.;Kubota;T.;et al.
- 通讯作者:et al.
TSU-68 (SU6668) inhibits local tumor growth and liver metastasis of human colon cancer xenografts via anti-angiogenesis.
TSU-68 (SU6668) 通过抗血管生成抑制人结肠癌异种移植物的局部肿瘤生长和肝转移。
- DOI:
- 发表时间:2005
- 期刊:
- 影响因子:0
- 作者:Yozrozuya;K;Kubota T;et al.
- 通讯作者:et al.
Twelve years' progress in surgery for perforated gastric and duodenal ulcers : a retrospective study of indications for laparoscopic surgery, post-operateive course and the influence of Candida infection.
胃十二指肠溃疡穿孔手术十二年进展:腹腔镜手术指征、术后病程及念珠菌感染影响的回顾性研究。
- DOI:
- 发表时间:2006
- 期刊:
- 影响因子:0
- 作者:Nakamura;T.;Yoshida;M.;Otani;Y.;Kameyama;K.;Ishikawa;H.;Kumai;K.;Kubota;T.;Saikawa;Y.;Kitajima;M.
- 通讯作者:M.
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
KUBOTA Tetsuro其他文献
KUBOTA Tetsuro的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('KUBOTA Tetsuro', 18)}}的其他基金
Chemo-resistance-related genes detected by cDNA microarray
cDNA微阵列检测化疗耐药相关基因
- 批准号:
14571225 - 财政年份:2002
- 资助金额:
$ 2.24万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
New strategy in cancel therapy with reference tomethionine-depletion
参考蛋氨酸消耗的取消治疗新策略
- 批准号:
07671329 - 财政年份:1995
- 资助金额:
$ 2.24万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Cloning of suppressor gene of metastasis using subtraction hybridization method
消减杂交法克隆转移抑制基因
- 批准号:
05671026 - 财政年份:1993
- 资助金额:
$ 2.24万 - 项目类别:
Grant-in-Aid for General Scientific Research (C)
Comparative study of concentrations of antitumor agents in serum and tumor in nude mouse and human
裸鼠与人血清及肿瘤中抗肿瘤药物浓度的比较研究
- 批准号:
62570579 - 财政年份:1987
- 资助金额:
$ 2.24万 - 项目类别:
Grant-in-Aid for General Scientific Research (C)
相似国自然基金
Entpd5在上皮性卵巢癌对Cisplatin继发耐药中的分子作用机制研究
- 批准号:81703078
- 批准年份:2017
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
构建基于TRAIL-exosome的siRNA和Cisplatin共载纳米系统及治疗耐药宫颈癌的研究
- 批准号:81671809
- 批准年份:2016
- 资助金额:58.0 万元
- 项目类别:面上项目
CUDC-101联合cisplatin对卵巢癌腹水细胞spheroid形成及转移机制的相关研究
- 批准号:81402127
- 批准年份:2014
- 资助金额:21.0 万元
- 项目类别:青年科学基金项目
NSAIDs增强卵巢癌细胞对顺铂、紫杉醇药物敏感性的机理研究
- 批准号:30772305
- 批准年份:2007
- 资助金额:28.0 万元
- 项目类别:面上项目
XPC表达变异改变膀胱尿路上皮癌对Cisplatin敏感性的实验研究
- 批准号:30340057
- 批准年份:2003
- 资助金额:9.0 万元
- 项目类别:专项基金项目
相似海外基金
悪性軟部腫瘍術後hypotonic cisplatin treatmentの検証
恶性软组织肿瘤术后低渗顺铂治疗的验证
- 批准号:
24K19630 - 财政年份:2024
- 资助金额:
$ 2.24万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Greatwall in replication stress/DNA damage responses and oral cancer resistance
长城在复制应激/DNA损伤反应和口腔癌抵抗中的作用
- 批准号:
10991546 - 财政年份:2024
- 资助金额:
$ 2.24万 - 项目类别:
Targeting the mutant promoter of Telomerase Reverse Transcriptase (TERT)
靶向端粒酶逆转录酶 (TERT) 的突变启动子
- 批准号:
10677899 - 财政年份:2023
- 资助金额:
$ 2.24万 - 项目类别:
Role of miR-195 in Chemo-Resistant Ovarian Cancer
miR-195 在化疗耐药性卵巢癌中的作用
- 批准号:
10640540 - 财政年份:2023
- 资助金额:
$ 2.24万 - 项目类别:
Mechanism-based combination therapy for cholangiocarcinoma
基于机制的胆管癌联合治疗
- 批准号:
10650049 - 财政年份:2023
- 资助金额:
$ 2.24万 - 项目类别:
Save Kidneys in Cisplatin Chemotherapy by blocking HDAC6
顺铂化疗中通过阻断 HDAC6 拯救肾脏
- 批准号:
10841270 - 财政年份:2023
- 资助金额:
$ 2.24万 - 项目类别:
Immunogenomic predictors of outcomes in patients with locally advanced cervical cancer treated with immunotherapy and chemoradiation
接受免疫治疗和放化疗的局部晚期宫颈癌患者结果的免疫基因组预测因子
- 批准号:
10908093 - 财政年份:2023
- 资助金额:
$ 2.24万 - 项目类别:
Development of miR-27a* for the Treatment of Head and Neck Squamous Cell Carcinoma
开发 miR-27a* 用于治疗头颈鳞状细胞癌
- 批准号:
10752726 - 财政年份:2023
- 资助金额:
$ 2.24万 - 项目类别:
Signaling basis of senescence-associated secretory phenotype and its implications in epithelial ovarian cancer
衰老相关分泌表型的信号基础及其在上皮性卵巢癌中的意义
- 批准号:
10731600 - 财政年份:2023
- 资助金额:
$ 2.24万 - 项目类别:
UBR5's mechanisms of action in tumorigenesis and immunoregulation
UBR5在肿瘤发生和免疫调节中的作用机制
- 批准号:
10659844 - 财政年份:2023
- 资助金额:
$ 2.24万 - 项目类别:














{{item.name}}会员




